Saka H - Search Results

1

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.

Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G Jr, Reck M, Wu YL, Brahmer JR, Felip E, Sawada T, Noguchi K, Han SR, Piperdi B, Kush DA, Lopes G. Nosaki K, et al. Among authors: saka h. Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8. Lung Cancer. 2019. PMID: 31446994

2

Ifosfamide, cisplatin, vinblastine combination chemotherapy in the treatment of advanced non-small-cell lung cancer.

Saito H, Shimokata K, Yamamoto M, Saka H, Sakai S, Kawachi H, Saito H. Saito H, et al. Among authors: saka h. Cancer Chemother Pharmacol. 1990;27(3):251-2. doi: 10.1007/BF00685723. Cancer Chemother Pharmacol. 1990. PMID: 2176135 Clinical Trial.

3

Cisplatin, etoposide, and vincristine combination chemotherapy in the treatment of non-small cell lung cancer.

Watanabe A, Ichiyama S, Shimokata K, Nagura E, Saito H, Saka H, Nomura F, Sakai S, Saito H. Watanabe A, et al. Among authors: saka h. Nagoya J Med Sci. 1993 Mar;55(1-4):41-6. Nagoya J Med Sci. 1993. PMID: 8247105

4

Phase II study of carboplatin, cisplatin, and vindesine in advanced non-small-cell lung cancer.

Saito H, Shimokata K, Saka H, Yamamoto M, Ogasawara T, Nomura F, Sakai S, Iwata M, Murate T, Miyachi T, et al. Saito H, et al. Among authors: saka h. Cancer Chemother Pharmacol. 1993;33(2):154-6. doi: 10.1007/BF00685334. Cancer Chemother Pharmacol. 1993. PMID: 8261575 Clinical Trial.

5

Phase II study of a 72-h concurrent continuous infusion of cisplatin and etoposide in advanced non-small-cell lung cancer.

Saito H, Shimokata K, Yamamoto M, Saka H, Sakai S, Saito H. Saito H, et al. Among authors: saka h. Cancer Chemother Pharmacol. 1993;32(2):134-6. doi: 10.1007/BF00685616. Cancer Chemother Pharmacol. 1993. PMID: 8387399 Clinical Trial.

6

Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer.

Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K. Ando Y, et al. Among authors: saka h. Jpn J Cancer Res. 1996 Feb;87(2):200-5. doi: 10.1111/j.1349-7006.1996.tb03159.x. Jpn J Cancer Res. 1996. PMID: 8609070 Free PMC article. Clinical Trial.

7

Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro.

Mogi H, Hasegawa Y, Watanabe A, Nomura F, Saka H, Shimokata K. Mogi H, et al. Among authors: saka h. Cancer Chemother Pharmacol. 1997;39(3):199-204. doi: 10.1007/s002800050560. Cancer Chemother Pharmacol. 1997. PMID: 8996520

8

Chemotherapy for small-cell lung cancer: more is not better.

Saka H, Shimokata K. Saka H, et al. Cancer Chemother Pharmacol. 1997;40 Suppl:S107-9. doi: 10.1007/s002800051071. Cancer Chemother Pharmacol. 1997. PMID: 9272144 Review.

9

A phase II study of carboplatin and prolonged administration of oral etoposide in patients with small-cell lung cancer.

Minami H, Saka H, Sakai S, Yamamoto M, Shimokata K. Minami H, et al. Among authors: saka h. Acta Oncol. 1997;36(7):765-9. doi: 10.3109/02841869709001352. Acta Oncol. 1997. PMID: 9490098 Clinical Trial.

10

[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].

Nishiwaki Y, Yano S, Tamura T, Nakagawa K, Kudoh S, Horai T, Noda K, Takata I, Watanabe K, Saka H, Takeda K, Imamura F, Matsui K, Katakami N, Yokoyama A, Sawa Y, Takada M, Kiura K, Sugiura T, Fukuoka M, Uchida H. Nishiwaki Y, et al. Among authors: saka h. Gan To Kagaku Ryoho. 2004 Apr;31(4):567-73. Gan To Kagaku Ryoho. 2004. PMID: 15114701 Clinical Trial. Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

638 results

Search Page